New Typhoid IgG/IgM Rapid Test

May 3, 2013 - PRLog -- HEMA DIAGNOSTIC SYSTEMS ANNOUNCES THE AVAILABILITY OF A
NEW RAPID DUAL DIAGNOSTIC TEST FOR TYPHOID IgG/IgM

Panama City, Republic of Panama- January 2013 –
   Hema Diagnostic Systems (HDS) announced today the availability of a new rapid Typhoid IgG/IgM assay for the detection and differentiation of IgG/IgM antibodies to S typhi in whole blood, serum or plasma.  The assay, known as the RAPID 1-2-3 HEMA® DUAL TYPHOID IgG/IgM  CASSETTE test is immediately available and will be in addition to our standard a RAPID 1-2-3 HEMA® EXPRESS® TYPHOID IgM  CASSETTE test.
   A febrile condition, Typhoid fever, is a bacterial infection caused by Salmonella serotypes including S. typhi, S. paratyphi A, S. paratyphi B and Salmonella sendai. The disease is transmitted through ingestion of food or water contaminated with feces or urine of infected persons. The symptoms of the illness include high fever, headache, abdominal pain, constipation and appearance of skin rashes.  Specific agglutens appeared during the course of most of the attacks during the second week of the infection. The tech bubble levels of IgM antibodies in S typhi appear and persist for four months. IgG antibodies are detected thereafter and remain in the blood for two years. The detection of IgM reveals acute typhoid in early stages of infection while the detection of both IgG and IgM suggests acute typhoid in the middle phase of the infection. In areas of high endemicity, where the rate of typhoid transmission is high, the detection of specific IgG increases.
   “The introduction of the RAPID 1-2-3 HEMA DUAL TYPHOID IgG/IgM CASSETTE offers a unique diagnostic device to the international market and meets the needs of multiple countries around the world. Now, increasing world health problems are being created by events such as climate-change related weather issues, war or basic sanitary conditions, all of which mandate our increased attention to those resulting diseases which appear sporadically and which require an immediate diagnostic response. The RAPID 1-2-3 HEMA DUAL TYPHOID IgG/IgM CASSETTE offers such a response”…according to Lawrence Salvo, President and CEO of Hema Diagnostic Systems.
   Mr. Salvo went on to say… “the initial design of our new RAPID 1-2-3 HEMA DUAL TYPHOID IgG/IgM CASSETTE device will be in our standard cassette format and will later be configured into our EXPRESS device format. The design and evaluation of our typhoid IgG/IgM diagnostic had been in process for a number of months. Only now do we find appropriate to announce its’ introduction as the need for such a diagnostic tool has been impressed upon us by HDS distributors around the world. Our cassette device format will allow a quick and easy introduction into field use, as the configuration of this cassette is identical to all of our other RAPID 1-2-3 HEMA CASSETTE formats.”
   Concerning the benefits of the diagnostic, Mr. Salvo went on to say: “typhoid is currently affects about 22 million people per year, with a current fatality rates for those who are positive for Typhoid and who remain untreated, as high as 10%...according the WHO statistics. However, when properly diagnosed and the subject administered the appropriate antibiotic therapy, that number is shown to shrink to 1%. Again, testing can save lives.”

   The packaging of the RAPID 1-2-3 HEMA® DUAL TYPHOID IgG/IgM CASSETTE is in the same presentation as all other HDS CASSETTE devices and includes lancet and an alcohol pad. With the ability to be stored at 4°-30°C room temperature and with the use of whole blood, the RAPID 1-2-3 HEMA® DUAL TYPHOID IgG/IgM CASSETTE can easily be incorporated into almost any emergency diagnostic situation and does not need electricity, special equipment, refrigeration or special training. It is user-friendly and cost-effective. It is designed to meet the needs of those in the field, in a clinic, laboratory or hospital using whole blood, serum/plasma.


About Hema Diagnostic Systems
Hema Diagnostic Systems is HDS is a privately held biotechnology company involved in the development, manufacture, assembly and distribution of diagnostics targeting primary as well as orphan infectious diseases. Incorporating rapid, Point-Of-Care test devices and a new and growing line of ELISA assays, Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are simple to use and highly cost effective when incorporated into Hema Diagnostic Systems’ patented delivery systems. The Rapid 1-2-3 Hema EXPRESS as well as the Rapid 1-2-3 Hema EZ® are novel delivery systems that are self contained and easy to use. Additionally, Hema Diagnostic Systems offers a complete and growing line of Rapid 1-2-3 Hema CASSETTE devices. HDS includes two ELISA assays under HDS’ QUANTIFLEXX® brand name.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results.